a16z Podcast
The Science and Supply of GLP-1s
Jun 19, 2024
Brooke Boyarsky-Pratt, the CEO of KnownWell, revolutionizes the obesity medicine landscape with her personal journey battling obesity. She discusses the critical role of obesity-specific practitioners and patient-centric medical homes in fostering trust. The conversation delves into the science and impact of GLP-1 medications, highlighting their tailored applications in treatment. The challenges of cost and supply in the obesity sector are addressed, alongside a vision for a more empathetic, comprehensive approach to obesity care.
45:08
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 drugs require personalized matching for effective weight management.
- Access to obesity care is crucial, emphasizing comprehensive treatment and tailored medication selection.
Deep dives
Redefining Obesity Care through NodeWell and GLP1s
NodeWell, led by Brooke Boyarsky-Pratt and A16Z's Benita Agarwalla, redefines obesity care with a patient-centric approach. Brooke's personal journey from being advised to attend a 'fat camp' to founding NodeWell highlights the need for comprehensive obesity treatment. The podcast explores GLP1s and their role in addressing obesity, emphasizing the importance of matching the right medication to individual patients for effective weight management. The dialogue underscores the significance of comprehensive obesity medicine that integrates behavioral health, nutrition programs, and medical care.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
